Lilly drug misses Phase III target

Share this article:

Eli Lilly's gastric cancer drug Cryamza failed to hit its primary Phase III liver cancer target.

The Indiana drugmaker announced Wednesday that although the drug did not show a statistically significant gain over placebo for overall survival, results indicated “meaningful improvements” in secondary measures including progression-free survival and overall response rate.

ISI analyst Mark Schoenebaum said in April that a hepatocellular cancer indication could be worth around $200 million in sales.

The drug has orphan status for hepatocellular cancer. Lilly is also exploring the drug's use in other cancers, including non-small cell lung cancer.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.